{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Siplizumab",
  "nciThesaurus": {
    "casRegistry": "288392-69-8",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A humanized monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth.",
    "fdaUniiCode": "KUW1QG1ZM3",
    "identifier": "C38685",
    "preferredName": "Siplizumab",
    "semanticType": "Immunologic Factor",
    "subclassOf": [
      "C20401"
    ],
    "synonyms": [
      "Immunoglobulin G1, Anti-(human CD2 (Antigen))(Human-rat Monoclonal MEDI-507 G1-chain), Disulfide with Human-rat Monoclonal MEDI-507 Light Chain, Dimer",
      "MEDI-507",
      "SIPLIZUMAB",
      "Siplizumab",
      "siplizumab"
    ]
  }
}